ResearcherHôpital CochinNo recent work listed

Victor Mortier

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5053332241. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2022: 1 paper

Papers 1

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. Co-author DOI 10.3390/cancers14246179 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Anna Pellat · 1 shared paper, 2022 · strength 0.15
- Paper Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as… DOI 10.3390/cancers14246179 ↗
Maxime Barat · 1 shared paper, 2022 · strength 0.15
- Paper Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as… DOI 10.3390/cancers14246179 ↗
Philippe A. Soyer · 1 shared paper, 2022 · strength 0.15
- Paper Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as… DOI 10.3390/cancers14246179 ↗
Ugo Marchèse · 1 shared paper, 2022 · strength 0.15
- Paper Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as… DOI 10.3390/cancers14246179 ↗
Romain Coriat · 1 shared paper, 2022 · strength 0.15
- Paper Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as… DOI 10.3390/cancers14246179 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.